TY - JOUR
T1 - The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant mycobacterium tuberculosis in hypoxia at neutral pH
AU - Iacobino, Angelo
AU - Giannoni, Federico
AU - Pardini, Manuela
AU - Piccaro, Giovanni
AU - Fattorini, Lanfranco
PY - 2019
Y1 - 2019
N2 - The activities of rifampin, nitazoxanide, PA-824, and sutezolid were tested against dormant Mycobacterium tuberculosis under conditions mimicking caseous granulomas (hypoxia at pH 7.3) in comparison with those of the combination rifampin-isoniazid-pyrazinamide-ethambutol (R-I-Z-E), which is used for human therapy. Mycobacterial viability was monitored by CFU and regrowth in MGIT 960. As shown by lack of regrowth in MGIT, rifampin-nitazoxanide-containing combinations, but not R-I-Z-E, killed dormant cells in 28 to 35 days. These observations might be important in designing new tuberculosis therapies.
AB - The activities of rifampin, nitazoxanide, PA-824, and sutezolid were tested against dormant Mycobacterium tuberculosis under conditions mimicking caseous granulomas (hypoxia at pH 7.3) in comparison with those of the combination rifampin-isoniazid-pyrazinamide-ethambutol (R-I-Z-E), which is used for human therapy. Mycobacterial viability was monitored by CFU and regrowth in MGIT 960. As shown by lack of regrowth in MGIT, rifampin-nitazoxanide-containing combinations, but not R-I-Z-E, killed dormant cells in 28 to 35 days. These observations might be important in designing new tuberculosis therapies.
KW - Hypoxia
KW - Mycobacterium tuberculosis
KW - Nitazoxanide
KW - PH
KW - Rifampin
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85068107595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068107595&partnerID=8YFLogxK
U2 - 10.1128/AAC.00273-19
DO - 10.1128/AAC.00273-19
M3 - Article
C2 - 31010861
AN - SCOPUS:85068107595
VL - 63
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 7
M1 - e00273-19
ER -